1,433 results match your criteria trial rtog


A Bayesian approach to tissue-fraction estimation for oncological PET segmentation.

Phys Med Biol 2021 Jun 14;66(12). Epub 2021 Jun 14.

Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, MO 63130, United States of America.

Tumor segmentation in oncological PET is challenging, a major reason being the partial-volume effects (PVEs) that arise due to low system resolution and finite voxel size. The latter results in tissue-fraction effects (TFEs), i.e. Read More

View Article and Full-Text PDF

Concurrent Chemoradiation in Anal Cancer Patients Delivered with Bone Marrow-Sparing IMRT: Final Results of a Prospective Phase II Trial.

J Pers Med 2021 May 18;11(5). Epub 2021 May 18.

Department of Oncology, Radiation Oncology, University of Turin, 10126 Turin, Italy.

We investigated the role of the selective avoidance of haematopoietically active pelvic bone marrow (BM), with a targeted intensity-modulated radiotherapy (IMRT) approach, to reduce acute hematologic toxicity (HT) in anal cancer patients undergoing concurrent chemo-radiation. We designed a one-armed two-stage Simon's design study to test the hypothesis that BM-sparing IMRT would improve by 20% the rate of G0-G2 (vs. G3-G4) HT, from 42% of RTOG 0529 historical data to 62% (α = 0. Read More

View Article and Full-Text PDF

Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ.

J Clin Oncol 2021 May 21:JCO2100831. Epub 2021 May 21.

Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale School of Medicine, New Haven, CT.

Purpose: Ductal carcinoma in situ (DCIS) accounts for 20% of breast cancer cases in the United States and is potentially overtreated, leading to high expenditures and low-value care. We conducted a cost-effectiveness analysis evaluating all adjuvant treatment strategies for DCIS.

Methods: A Markov model was created with six competing treatment strategies: observation, tamoxifen (TAM) alone, aromatase inhibitor (AI) alone, radiation treatment (RT) alone, RT + TAM, and RT + AI. Read More

View Article and Full-Text PDF

Validating Modern NRG Oncology Pelvic Nodal and GFRU Prostate Bed Contouring Guidelines for Post-prostatectomy Salvage Radiation: A Secondary Analysis of the LOCATE Trial.

Int J Radiat Oncol Biol Phys 2021 May 17. Epub 2021 May 17.

Department of Radiation Oncology, Stritch School of Medicine, Loyola University Chicago. Electronic address:

Purpose: We used the patterns of recurrence on F-fluciclovine PET/CT in post-prostatectomy patients enrolled in the XXXX trial to evaluate how well the most recent NRG Oncology and Groupe Francophone de Radiothérapie Urologique (GFRU) contouring recommendations encompassed all sites of recurrence in the prostate fossa and pelvic nodes in comparison to former Radiation Therapy Oncology Group (RTOG) recommendations.

Methods: Patients with biochemically recurrent prostate cancer after radical prostatectomy with a positive finding within the prostate fossa or pelvic nodes on F-fluciclovine PET/CTs were identified from the XXXX patient population. Areas of gross disease were delineated. Read More

View Article and Full-Text PDF

Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.

Lung Cancer 2021 06 18;156:68-71. Epub 2021 Apr 18.

University of Chicago Comprehensive Cancer Center, Chicago, IL, United States.

Introduction: The CALGB 30610/RTOG 0538 randomized trial was designed to test whether high-dose thoracic radiotherapy (TRT) would improve survival compared with 45 Gy twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC). Two piloted experimental TRT regimens were of interest to study, 70 Gy daily (QD) and 61.2 Gy concomitant boost (CB). Read More

View Article and Full-Text PDF

Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.

PLoS One 2021 14;16(4):e0249123. Epub 2021 Apr 14.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, United States of America.

Purpose: The Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool are unknown, limiting our ability to perform cost-utility analyses. This study aimed to map EPIC tool to EuroQoL-5D-3L (EQ5D) to generate EQ5D health utilities.

Methods And Materials: This is a secondary analysis of a prospective, randomized non-inferiority clinical trial, conducted between 04/2006 and 12/2009 at cancer centers across the United States, Canada, and Switzerland. Read More

View Article and Full-Text PDF

Concordance of the WHO, RTOG, and CTCAE v4.0 grading scales for the evaluation of oral mucositis associated with chemoradiation therapy for the treatment of oral and oropharyngeal cancers.

Support Care Cancer 2021 Mar 31. Epub 2021 Mar 31.

Primary Endpoint Solutions, Waltham, MA, USA.

Background: The ability to consistently and accurately assess oral mucositis (OM) is critical to descriptions of its incidence and severity and in evaluating the effectiveness of potential interventions. The lack of a single grading scale compounds outcome interpretation. Consequently, we assessed the concordance of three of the most commonly used OM grading criteria (World Health Organization (WHO), Radiation Therapy Oncology Group (RTOG), and the common terminology criteria for adverse events (CTCAE). Read More

View Article and Full-Text PDF

Randomized placebo-controlled phase II trial of high-dose melatonin mucoadhesive oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing radiation therapy concurrent with systemic treatment.

Clin Transl Oncol 2021 Mar 18. Epub 2021 Mar 18.

Institut Català d'Oncologia (ICO), Hospital Durán I Reynals, Avda de la Granvia de l'Hospitalet, 199, L'Hospitalet, 08907, Barcelona, Spain.

Purpose: The objective of this trial was to evaluate the safety and efficacy of melatonin oral gel mouthwashes in the prevention and treatment of oral mucositis (OM) in patients treated with concurrent radiation and systemic treatment for head and neck cancer.

Methods: Randomized, phase II, double-blind, placebo-controlled trial (1:1 ratio) of 3% melatonin oral gel mouthwashes vs. placebo, during IMRT (total dose ≥ 66 Gy) plus concurrent Q3W cisplatin or cetuximab. Read More

View Article and Full-Text PDF

Intensity modulated radiotherapy for anal canal squamous cell carcinoma: A 16-year single institution experience.

Clin Transl Radiat Oncol 2021 May 23;28:17-23. Epub 2021 Feb 23.

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.

Introduction: To report long-term efficacy and adverse events (AEs) associated with intensity modulated radiotherapy (IMRT) for patients with anal canal squamous cell carcinoma (ASCC).

Materials And Methods: This was a retrospective review of patients with ASCC who received curative-intent IMRT and concurrent chemotherapy (98%) between 2003 and 2019. Overall survival (OS), colostomy-free survival (CFS), and progression-free survival (PFS) were estimated using the Kaplan-Meier method. Read More

View Article and Full-Text PDF

Post-Operative Accelerated-Hypofractionated Chemoradiation With Volumetric Modulated Arc Therapy and Simultaneous Integrated Boost in Glioblastoma: A Phase I Study (ISIDE-BT-2).

Front Oncol 2020 22;10:626400. Epub 2021 Feb 22.

Radiation Oncology Unit, Gemelli Molise Hospital - Università Cattolica del Sacro Cuore, Campobasso, Italy.

Background: Glioblastoma Multiforme (GBM) is the most common primary brain cancer and one of the most lethal tumors. Theoretically, modern radiotherapy (RT) techniques allow dose-escalation due to the reduced irradiation of healthy tissues. This study aimed to define the adjuvant maximum tolerated dose (MTD) using volumetric modulated arc RT with simultaneous integrated boost (VMAT-SIB) plus standard dose temozolomide (TMZ) in GBM. Read More

View Article and Full-Text PDF
February 2021

The Definition and Delineation of the Target Area of Radiotherapy Based on the Recurrence Pattern of Glioblastoma After Temozolomide Chemoradiotherapy.

Front Oncol 2020 22;10:615368. Epub 2021 Feb 22.

Department of Radiation Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Radiotherapy is an important treatment for glioblastoma (GBM), but there is no consensus on the target delineation for GBM radiotherapy. The Radiation Therapy Oncology Group (RTOG) and European Organisation for Research and Treatment of Cancer (EORTC) each have their own rules. Our center adopted a target volume delineation plan based on our previous studies. Read More

View Article and Full-Text PDF
February 2021

Efficacy of sucralfate ointment in the prevention of acute proctitis in cancer patients: A randomized controlled clinical trial.

Caspian J Intern Med 2020 ;11(4):410-418

Gastrointestinal Cancer Research Center, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Background: Acute radiation proctitis (ARP) is a usual adverse effect in patients undergoing pelvic radiotherapy. The symptoms include diarrhea, rectal blood or mucus discharge, fecal urgency and tenesmus with pain. Sucralfate, an aluminum-based salt of sucrose octasulfate, is a cytoprotective agent that forms a coating barrier at injured sites by adhering to mucoproteins. Read More

View Article and Full-Text PDF
January 2020

Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

Oral Oncol 2021 May 25;116:105241. Epub 2021 Feb 25.

Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, United States.

Objectives: To develop nomograms predicting overall survival (OS), freedom from locoregional recurrence (FFLR), and freedom from distant metastasis (FFDM) for patients receiving chemoradiation for laryngeal squamous cell carcinoma (LSCC).

Material And Methods: Clinical and treatment data for patients with LSCC enrolled on NRG Oncology/RTOG 0129 and 0522 were extracted from the RTOG database. The dataset was partitioned into 70% training and 30% independent validation datasets. Read More

View Article and Full-Text PDF

A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study.

Oncologist 2021 Jun 11;26(6):523-532. Epub 2021 Mar 11.

Department of Hematology Oncology, Cleveland Clinic, Cleveland, Ohio, USA.

ECOG-ACRIN EA5181 is a phase III prospective, randomized trial that randomizes patients undergoing chemo/radiation for locally advanced non-small cell lung cancer (LA-NSCLC) to concomitant durvalumab or no additional therapy, with both arms receiving 1 year of consolidative durvalumab. Radiation dose escalation failed to improve overall survival in RTOG 0617. However, conventionally fractionated radiation to 60 Gy with concomitant chemotherapy is associated with a high risk of local failure (38%-46%). Read More

View Article and Full-Text PDF

Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.

JAMA Oncol 2021 Apr;7(4):544-552

Department of Radiation Oncology, Johns Hopkins University, Baltimore, Maryland.

Importance: Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with prostate cancer.

Objective: To validate the GC in the context of a randomized phase 3 trial.

Design, Setting, And Participants: This ancillary study used RP specimens from the phase 3 placebo-controlled NRG/RTOG 9601 randomized clinical trial conducted from March 1998 to March 2003. Read More

View Article and Full-Text PDF

One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.

BMC Cancer 2021 Feb 8;21(1):140. Epub 2021 Feb 8.

Department of Medical Oncology, Beaumont Hospital, Dublin 9, Ireland.

Background: Following optimal local therapy, adjuvant Procarbazine, Lomustine and Vincristine (PCV) improves overall survival (OS) in low-grade glioma (LGG). However, 1 year of PCV is associated with significant toxicities. In the pivotal RTOG 9802 randomised control trial, approximately half of the patients discontinued treatment after 6 months. Read More

View Article and Full-Text PDF
February 2021

Patient-Reported Outcomes From a Phase 3 Randomized Controlled Trial Exploring Optimal Sequencing of Short-Term Androgen Deprivation Therapy With Prostate Radiation Therapy in Localized Prostate Cancer.

Int J Radiat Oncol Biol Phys 2021 Jan 30. Epub 2021 Jan 30.

Radiation Medicine Program, The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Division of Radiation Oncology, Department of Radiology, University of Ottawa, Ottawa, Ontario, Canada. Electronic address:

Purpose: Two phase 3 randomized controlled trials (OTT-0101, RTOG-9413) and a meta-analysis have shown an impact of sequencing of androgen deprivation therapy (ADT) and radiation therapy on oncologic outcomes in prostate cancer (PCa). However, the impact of sequencing strategy on health-related quality of life (HR-QoL) is unclear. Here, we present the patient-reported HR-QoL outcomes from the OTT-0101 study. Read More

View Article and Full-Text PDF
January 2021

Neurocognitive, Symptom, and Health- Related Quality of Life Outcomes of a Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma (NRG/RTOG 0825).

Neuro Oncol 2021 Jan 30. Epub 2021 Jan 30.

University of Maryland, Baltimore, MD.

Background: Results of NRG Oncology RTOG 0825 reported adding bevacizumab to standard chemoradiation did not significantly improve survival endpoints and resulted in greater decline in neurocognitive function (NCF) and patient reported outcomes (PRO) over time in bevacizumab treated patients. The present report provides additional results of patient centered outcomes over time and their prognostic association with survival endpoints.

Methods: NCF tests, MD Anderson Symptom Inventory brain tumor module (MDASI-BT), and European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire with brain-cancer module (QLQ-C30/BN20) were completed in a subset of progression-free patients at baseline and longitudinally. Read More

View Article and Full-Text PDF
January 2021

Stereotactic body radiotherapy as a boost after external beam radiotherapy for high-risk prostate cancer patients.

Indian J Cancer 2020 Nov 2. Epub 2020 Nov 2.

Radiation Oncology Department, Okmeydani Research and Education Hospital, Sisli, Istanbul, Turkey.

Background: The effect of high-dose-rate (HDR) brachytherapy after external radiation in high-risk prostate cancer patients has been proven. Stereotactic body radiotherapy as a less invasive method has similar dosimetric results with HDR brachytherapy. This study aims to evaluate the prostate-specific antigen (PSA) response, acute side effects, and quality of life of patients who underwent stereotactic body radiotherapy (SBRT) as a boost after pelvic radiotherapy (RT). Read More

View Article and Full-Text PDF
November 2020

Assessment of acute toxicities and early local recurrences in post mastectomy breast cancer patients by accelerated hypofractionated radiotherapy; a single arm clinical trial.

J BUON 2020 Sep-Oct;25(5):2265-2270

Department of Radiation Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Gorimedu, Pondicherry, India.

Purpose: Hypofractionated post mastectomy radiotherapy (PMRT) is commonly given using conventional radiotherapy technique. Volumetric modulated arc therapy (VMAT) and Intensity modulated radiation therapy (IMRT) are better sparing heart and lungs. This study was conducted to assess the toxicity profile and dosimetry outcomes of patients receiving PMRT using IMRT or VMAT. Read More

View Article and Full-Text PDF
December 2020

A narrative review of toxicity of chemoradiation and immunotherapy for unresectable, locally advanced non-small cell lung cancer.

Transl Lung Cancer Res 2020 Oct;9(5):2040-2050

Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, USA.

Despite declining smoking rates, lung cancer remains the second most common malignancy in the United States and the leading cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) comprises roughly 85% of cases, and patients tend to present with advanced disease. Historically, concurrent chemoradiotherapy (CRT) has been the standard of care for stage III unresectable NSCLC but outcomes even with multimodal therapy have remained relatively poor. Read More

View Article and Full-Text PDF
October 2020

Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617.

Int J Radiat Oncol Biol Phys 2021 Apr 13;109(5):1619-1626. Epub 2020 Nov 13.

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York.

Purpose: Contouring inconsistencies are known but understudied in clinical radiation therapy trials. We applied auto-contouring to the Radiation Therapy Oncology Group (RTOG) 0617 dose escalation trial data. We hypothesized that the trial heart doses were higher than reported due to inconsistent and insufficient heart segmentation. Read More

View Article and Full-Text PDF

Long-Term Results of NRG Oncology/RTOG 0321: A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiation Therapy for Adenocarcinoma of the Prostate.

Int J Radiat Oncol Biol Phys 2021 Jul 10;110(3):700-707. Epub 2020 Nov 10.

Cedars-Sinai Medical Center.

Purpose: To report the long-term outcome of patients with prostate cancer treated with external beam radiation therapy and high dose rate (HDR) brachytherapy from a prospective multi-institutional trial conducted by NRG Oncology/RTOG.

Methods And Materials: Patients with clinically localized (T1c-T3b) prostate cancer without prior history of transurethral resection of prostate or hip prosthesis were eligible for this study. All patients were treated with a combination of 45 Gy in 25 fractions from external beam radiation therapy and one HDR implant delivering 19 Gy in 2 fractions. Read More

View Article and Full-Text PDF

Bone Marrow-Sparing IMRT in Anal Cancer Patients Undergoing Concurrent Chemo-Radiation: Results of the First Phase of a Prospective Phase II Trial.

Cancers (Basel) 2020 Nov 9;12(11). Epub 2020 Nov 9.

Department of Oncology, Radiation Oncology, University of Turin, 10126 Turin, Italy.

Purpose: to investigate the role of selective avoidance of hematopoietically active BM within the pelvis, as defined with FDG-PET, employing a targeted IMRT approach, to reduce acute hematologic toxicity (HT) profile in anal cancer patients undergoing concurrent chemo-radiation.

Methods: a one-armed two-stage Simon's design was selected to test the hypothesis that BM-sparing approach would improve by 20% the rate of G0-G2 (vs. G3-G4) HT, from 42% of RTOG 0529 historical data to 62% (α = 0. Read More

View Article and Full-Text PDF
November 2020

Stereotactic radiotherapy with focal boost for intermediate and high-risk prostate cancer: Initial results of the SPARC trial.

Clin Transl Radiat Oncol 2020 Nov 20;25:88-93. Epub 2020 Oct 20.

Royal Marsden NHS Foundation Trust, 203 Fulham Road, London SW3 6JJ, UK.

Introduction: Dose escalation to dominant intraprostatic lesions (DILs) is a novel method to increase the therapeutic ratio in localised prostate cancer. The Stereotactic Prostate Augmented Radiotherapy with Cyberknife (SPARC) trial was designed to determine the feasibility of a focal boost defined with multiparametric magnetic resonance imaging (mpMRI) using stereotactic ablative body radiotherapy (SABR).

Materials And Methods: Patients were included with newly diagnosed intermediate to high risk prostate cancer with at least one of: Gleason score 4 + 3, stage T3a, or PSA > 20 ng/ml. Read More

View Article and Full-Text PDF
November 2020

Accelerated Partial Breast Irradiation (APBI): Where Are We Now?

Curr Breast Cancer Rep 2020 Oct 18:1-10. Epub 2020 Oct 18.

Department of Oncology, McMaster University and Juravinski Cancer Centre, 699 Concession Street, Hamilton, ON L8V 5C2 Canada.

Purpose Of Review: Accelerated partial breast irradiation (APBI) is an alternative approach to breast conserving therapy (BCT) where radiation (RT) is delivered over a shorter period of time compared with whole breast irradiation (WBI), resulting in improved patient convenience and cost savings. APBI can be delivered using brachytherapy, intraoperative RT, or conformal external beam radiation therapy (EBRT) techniques. In this review, the authors appraise the latest modern randomized controlled trials (RCTs) of APBI and discuss the application of the data to clinical practice. Read More

View Article and Full-Text PDF
October 2020

Skin toxicity following radiotherapy in patients with breast carcinoma: is anthocyanin supplementation beneficial?

Clin Nutr 2021 Apr 6;40(4):2068-2077. Epub 2020 Oct 6.

Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli, IS, Italy. Electronic address:

Background: The EU-supported ATHENA project stems from a previous study suggesting that moderate wine consumption reduced the side-effects of radiotherapy (RT) in breast cancer patients, an effect possibly due to non-alcoholic anthocyanin fractions of wine.

Objective: To evaluate the role of anthocyanins on RT skin side effects in breast cancer patients.

Methods: Randomized, controlled, double-blind clinical trial. Read More

View Article and Full-Text PDF

Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy.

Strahlenther Onkol 2021 Jan 24;197(1):63-73. Epub 2020 Sep 24.

German Cancer Research Center (DKFZ), Heidelberg, Germany.

Purpose: To determine the effect of Cystus® tea (Naturprodukte Dr. Pandalis GmbH & Co. KG) as mouthwash compared to sage tea on oral mucositis in patients undergoing radio(chemo)therapy for head and neck cancer. Read More

View Article and Full-Text PDF
January 2021

Efficacy of topical Calendula officinalis on prevalence of radiation-induced dermatitis: A randomised controlled trial.

Australas J Dermatol 2021 Feb 23;62(1):e35-e40. Epub 2020 Sep 23.

Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, Australia.

Objectives: A randomised controlled trial was undertaken to compare the efficacy of topical Calendula officinalis (Calendula) versus standard of care (Sorbolene: 10% glycerine in cetomacragol cream) in reducing the prevalence of radiation-induced dermatitis in women undergoing breast cancer radiotherapy.

Methods: A total of 271 women were screened and 82 were randomised. The primary outcome was prevalence of acute radiation-induced dermatitis (RTOG grade 2+) assessed at multiple skin sites. Read More

View Article and Full-Text PDF
February 2021

Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer.

Transl Lung Cancer Res 2020 Aug;9(4):1472-1482

Department of Radiation Oncology, Cancer Hospital of University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.

Background: Previous research has shown that stereotactic body radiation therapy (SBRT) can achieve a high level of tumor control in patients with early-stage non-small cell lung cancer (NSCLC). However, to date, such studies have mainly focused on peripheral early-stage patients. This study aimed to assess the clinical outcomes and toxicity of patients with central lung cancer treated with SBRT in our institution. Read More

View Article and Full-Text PDF